Biomaterials Submission Guide: Scope, Format & Editor Priorities

The best Biomaterials submissions are easy to read as decision documents.

The editor should quickly see:

• the biological problem
• the material intervention
• the evidence chain
• the application claim

That means the manuscript should not bury critical biological data late or hide the comparator that makes the result meaningful.

Figures

• Histology, microscopy, release profiles, and biological assays need to be readable and organized
• Keep figures argument-driven, not just data-dense
• If one figure carries the translational claim, it must be exceptionally clear

Methods

• Preparation, sterilization, assay setup, model choice, and statistical handling need enough detail to be trusted
• If ethics-sensitive work is involved, make sure those statements are complete before submission

One common weakness in borderline submissions is that the data arrives in the wrong order. The manuscript often reads better when the results move from material design to interface behavior to biological consequence.

A stronger sequence usually looks like this:

• fabrication or formulation logic
• structure and surface characterization
• interfacial behavior, degradation, or release logic
• biological response in the relevant model
• interpretation of why the response changed

That ordering helps the editor see that the biology is part of the scientific story rather than an afterthought.

The cover letter should answer a simple question: why is this a Biomaterials paper rather than just a materials paper with biology attached?

The strongest letters usually do three things:

1. define the biological or clinical problem
2. explain the material intervention
3. state what the evidence proves

Keep the claims honest. A careful, credible letter helps more than an inflated one.

On a first pass, editors are usually not asking whether the material is interesting in the abstract. They are asking whether the manuscript earns the biological and translational language it uses.

That means the opening sections should make it easy to see:

• what biological problem is being addressed
• why the material design is relevant to that problem
• what evidence level the paper actually reaches
• whether the claimed application is supported or only aspirational

If the story only works when the reader is generous, it is not ready for this journal.

You should assume a serious review cycle. Biomaterials papers often need referees who understand both the materials side and the biological side, which can slow the process. If the manuscript is selected for review, expect the process to take time and expect revision requests to focus on evidence depth, controls, or the limits of the application claim.

If the fit is not clean, that is often a journal-selection problem rather than a science-quality problem.

Common alternatives include:

• Acta Biomaterialia for strong mechanistic biomaterials work
• Bioactive Materials for especially strong translational or regenerative stories
• Journal of Biomedical Materials Research for more specialized or narrower biomaterials papers
• broader materials journals when the real contribution is materials design more than biological consequence

Choose the venue that matches what the paper actually proves.

Many biomaterials papers lose time because the authors submit to the most flattering journal label instead of the journal that actually matches the evidence. If the manuscript is mechanistically strong but narrower, Acta Biomaterialia may be the cleaner path. If the biology is still modest, a broader materials or biomedical-engineering venue may be the more defensible target.

That is not settling. It is reducing avoidable desk rejection.

Even strong biomaterials papers are often revised in the same directions:

• a cleaner comparator or benchmark
• a stronger mechanistic explanation at the interface
• additional biological controls
• a more disciplined discussion of what the data does and does not support

That pattern is useful because it tells you what to improve before reviewers ask for it.

A simple pre-submit check is to ask whether the paper still sounds persuasive if you remove the adjectives and look only at the evidence chain. Can a skeptical reader see the biological problem, the material intervention, the comparator, and the level of support for the application claim? If not, the manuscript may still be relying on narrative confidence instead of proof.

That is usually the difference between a paper that gets a fair reading and one that looks oversold before review even starts.

1. Recent Biomaterials papers used to benchmark framing, evidence depth, and figure patterns
2. Comparable biomaterials-journal guidance used to distinguish Biomaterials from adjacent venues